Phenothiazines and butyrophenones are known to alter dopamine (3,4-dihydroxyphenethylamine) metabolism in the brain in a fashion suggesting that they may block dopamine receptors. We observed, using Dreiding molecular models, that dopamine in its solid-state conformation is superimposable upon a portion of the known x-ray structure of chlorpromazine 12-chloro-10-(3-dimethylaminopropyl)-phenothiazine]. The ability of phenothiazine drugs to mimic the dopamine-like conformation correlates with their antischizophrenic efficacy. These structure-activity relationships explain the importance of a substituent in ring a, a three-carbon side chain bearing the amino group, and a hetero atom between rings a and c.
The mechanism of the antischizophrenic action of phenothiazines and butyrophenones is obscure (1) (2) (3) . No single animal test uniformly predicts the antischizophrenic drug activity. However, a number of drug effects in animals correlate well with the antischizophrenic activity in man (4) . Some of the most sensitive of these procedures are suppression of conditioned avoidance responding (5) and antagonism to apomorphine, and amphetamine (dl-a-methylphenethylamine) induced stereotyped behavior (6) . The constellation of animal effects that best predict antischizophrenic drug activity has been designated "neuroleptic" (7) .
Phenothiazines and butyrophenones alter dopamine (3,4-dihydroxyphenethylamine) metabolism in a fashion suggesting that they block dopamine receptors in the brain (8) (9) (10) ; there is direct evidence that they also block dopamine receptors in the peripheral nervous system (11, 12) . Blockade of dopamine receptors in the corpus striatum in the brain might account for the extrapyramidal side effects, since the symptoms of idiopathic Parkinson's disease are attributable to dopamine deficiency in this brain region. Phenothiazines and butyrophenones that are more potent, on a milligram basis, as antipsychotic agents are correspondingly more potent in eliciting extrapyramidal side effects (13) and in augmenting dopamine turnover in the brain, an indirect reflection of dopamine receptor blockade (8) (9) (10) . Interestingly, despite the synthesis of a large number of phenothiazines and butyrophenones, it has not been possible to separate the antipsychotic and apparent dopamine receptor blocking actions.
Recently, the molecular structure of chlorpromazine [2- X-ray analysis clearly shows an orientation of the side chain of chlorpromazine away from the mid-line toward the chlorine-substituted aromatic ring (Fig. 1) . The x-ray analysis of dopamine shows the side chain fully extended and in a plane above the benzene ring, i.e., in the anti conformation (Fig. 1) .
From this figure, it can be seen that dopamine can be almost perfectly superimposed upon a portion of the chlorpromazine molecule. The aromatic ring of dopamine lies over ring a of chlorpromazine such that the meta-hydroxyl group overlays the sulphur atom of chlorpromazine. The primary-amine function of the fully extended side chain of dopamine would then be superimposed upon the tertiary amine group of the side chain of chlorpromazine. Kier and Truitt (16) , using the approximations of the Huckel molecular orbital theory, have suggested that the perferred conformation of dopamine is gauche.
The similarity of the dopamine conformation to part of the chlorpromazine structure suggests that phenothiazines might exert some of their clinical effects by interacting with dopamine-related sites. If so, the ability of phenothiazine drugs to assume a conformation resembling dopamine should be related to their antischizophrenic activity. This hypothesis can explain several important structure-activity relationships that determine the clinical antischizophrenic activity of phenothiazines.
(1). The extrapyramidal side effects of the phenothiazines, presumably attributable to the blockade of dopamine receptors in the corpus striatum, could be accounted for by phenothiazines mimicking the conformation of dopamine and blocking its receptor sites in the corpus striatum.
(2) The existence of a substituent in the a ring of the phenothiazines is crucial for antischizophrenic activity. The substituent should be at position 2 to obtain maximal activity (13) . The decrease in potency when the substituent on position 2 is moved to other positions is not due to an alteration in physical properties such as membrane activity, ionization constants, lipid solubility, or the ability to penetrate the blood-brain barrier (17) . If there were no substituent on the a ring, rings a and c would be almost symmetrical, and one would not expect the side chain to be oriented selectively either towards ring a or c. Such molecules, therefore, would not assume a chlorpromazinelike conformation. Accordingly, chlorpromazine analogues lacking a-ring substituents should be less effective antischizophrenic agents. Of all the phenothiazines widely used in treating schizophrenia, only promazine [10-(3-Dimethylaminopropyl)phenothiazine] and mepazine-10-[(1-Methyl-3-piperidyl)methyl]phenothiazine -lack a substituent on ring a, and these two agents are significantly less clinically effective than those embodying a substituent on ring a (18) . Although the conformation of promazine and mepazine have not yet been determined, the x-ray structure of other unsubstituted phenothiazines is known. Specifically, diethazine [10- (19) (20) (21) . Different substituents in position 2 vary in their ability to enhance neuroleptic activity. Although the most potent phenothiazines contain electron-withdrawing substituents on the 2-position, their electron-withdrawing character does not fully account for their enhanced potency, since electron-donating alkyl substituents on the 2-position also increase the neuroleptic activity (13) . (3) A major requirement for the antischizophrenic activity of phenothiazines is that the basic amino group be separated by three carbon atoms from the ring system. Shortening or branching of the side chain generally leads to a decreased neuroleptic activity (13) . Examples of phenothiazines with 2-carbon side chains that appear to lack antischizophrenic activity include promethazine and diethazine (13) . Molecular models indicate that with a 2-carbon side chain or with a branched 3-carbon side chain, van der Waal's repulsive forces between the side chain and the ring would make the assumption of the dopamine-like conformation less likely. However, the x-ray structures of phenothiazines substituted in ring a with a 2-carbon or branched side chain are not yet known. metrical isomers of the same rigid compounds whose side chains are fixed in a position that prohibits this assumption. The thioxanthenes, xanthenes, and dibenzoxepins contain an exocyclic double bond which replaces nitrogen in the ring system (Fig. 2) . If the ring is substituted, they can exist in a cis form with the side chain folded toward the a ring, or in a trans form within the side chain folded toward the c ring (22, 23) . The cis forms of these compounds are considerably more potent neuroleptics in animals than are the trans isomers (13) . Of these two isomers, only the cis forms can assume a conformation resembling the solid-state structure of chlorpromazine.
(5) A hetero atom para to position 2 that has a free single pair of electrons is important for antischizophrenic activity (13) . For instance, the tricyclic antidepressants that lack this hetero atom are only weak neuroleptics, even if as in chlorimipramine they contain a substituent in position 2. As depicted in Fig. 1 , the meta-hydroxyl of dopamine would overlie the hetero atom of ring b. Conceivably, the hetero atom might then interact with the site normally occupied by the meta-hydroxyl of the catecholamine. Of course, if the aromatic ring of dopamine rotates, no hydroxyl would overlay the hetero atom of ring b.
The butyrophenones, pharmacologically, are very much like the phenothiazines, but superficially seem to differ in molecular structure. Attention has been drawn to the fact that the butyrophenones have certain molecular features in com- mon with y-aminobutyric acid [24, 25] . Although their exact conformation in solid-state or solution has not yet been determined, molecular models indicate that the butyrophenone haloperidol (Fig. 3) could assume a conformation resembling portions of the phenothiazine molecule. For example, the three carbons separating the amine function from the carbonyJ moiety of haloperidol may be analogous to the 3-carbon side chain of the phenothiazines. In this case, the piperidine ring of the butyrophenones would correspond to the side-chain amine or piperazine of the phenothiazines, but the characteristic substituent at position 2 in the phenothiazines would not be present.
The similarity of the phenothiazine conformation to that of dopamine would also apply to norepinephrine, whose x-ray structure is similar to that of dopamine (26) . We have emphasized dopamine in this paper, because the more potent phenothiazines and butyrophenones seem to have greater apparent blocking activity at dopamine than at norepinephrine receptors (8) (9) (10) . There are several dopamine neuronal tracts in the brain (27) . The nigrostriatal system accounts for the greatest proportion of dopamine neurons, and presumably is involved in mediating the extrapyramidal effects of the phenothiazines. There also exist dopamine tracts that originate in the brain stem and send terminals to the nucleus accumbens of the septum and to the olfactory tubercle (27) . These latter two brain regions have been implicated in the mediation of apomorphine-induced stereotypic behavior in rats (28) , an animal model of amphetamine psychosis. Conceivably the antischizophrenic activity of the phenothiazines and butyrophenones, and their extrapyramidal side effects, might be attributable to interactions with dopamine receptors in the brain. Perhaps the dopamine tracts that terminate in the nucleus accumbens and olfactory tubercle are involved in the antischizophrenic activity of the phenothiazines and butyrophenones.
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